Company intelligence / Profile preview

Exonox Biosciences, Inc.

Ownership: Private
Development stage: Preclinical

Overview

Exonox Biosciences develops exosome-based solutions for disease diagnosis and therapy. Their main focus is on non-invasive liquid biopsy technologies using blood, plasma/serum, urine, etc., to identify disease-specific biomarkers with high specificity and sensitivity. No published late-stage clinical results or FDA-approved products from this company as of 2025[6][8].

Therapeutic areas: Oncology
Modalities: ExosomesBiomarkers (proteins, small-molecule metabolites)
Industry: Molecular Diagnostics

Beyond the preview

Go deeper on Exonox Biosciences, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Exonox Biosciences, Inc..

Explore the full profile